Cimzia Keeps Raking In The Cash As UCB Waits For New Products Impact
TNF Blocker Peaks Early
The Belgian group’s older products helped push 2022 revenues to the top of their guidance range as the peak sales forecast for the new epilepsy drug Fintepla is set at €800m.
